KAHR Medical Ltd., a Jerusalem, Israel-based biopharmaceutical company developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins known as Dual Signaling Proteins (“DSP”), raised US$18m funding round.
The round – whose completion is subject to customary closing conditions and is expected to occur early next month – was led by Flerie Invest, Oriella Limited, Hadasit Bio-Holdings (HBL), Pavilion Capital and Mirae Asset Venture Investment.
Proceeds will be used for advancing the company’s immuno-oncology drug candidates including the clinical development of its lead product, DSP107, an anti-CD47 therapy for the treatment of solid tumors through a Phase I/II study and the preclinical advancement of additional pipeline projects.
In September 2019, Kahr Medical announced a clinical collaboration with Roche to evaluate DSP107 in combination with Roche’s PD-L1-blocking checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced NSCLC who are refractory to existing immune checkpoint inhibitors
Led by Yaron Pereg, Ph.D., CEO, KAHR Medical expects to begin a Phase I/II trial in H2 2020 at leading sites in the US to evaluate DSP107 as a monotherapy and in combination with atezolizumab, following the filing of an Investigational New Drug (IND) application with the U.S. Food Drug Administration (FDA).